Cell membrane blebbing, chromatin condensation, genomic DNA fragmentation, and the exposure of particular phagocytosis signaling molecules on the cell surface are just a few of the distinctive morphological and biochemical features of the cell death process known as apoptosis. Apoptosis-initiated cell death is distinct from necrosis-induced cell death. Apoptotic death, in contrast, is silent and orderly. Necrotic cells are typically recognized as a danger signal by the immune system, which causes inflammation.
There are two main methods for inducing apoptotic cell death: The intrinsic pathway, also known as the Bcl-2-regulated or mitochondrial pathway, is strictly regulated by the BCL-2 family of proteins and is activated by a variety of developmental cues or cytotoxic insults, such as viral infection, DNA damage, and growth-factor deprivation.The tumor necrosis factor (TNF) receptor family members, such as Fas or TNF receptor-1 (TNFR1), which contain an intracellular death domain and can recruit and activate caspase-8 through the adaptor protein Fas-associated death domain (FADD; also known as MORT1) at the cell surface, are what initiate the extrinsic or death-receptor pathway. Without the involvement of the BCL-2 family, this recruitment results in the subsequent activation of downstream (effector) caspases like caspase-3, -6, or -7.
Numerous human diseases, including cancer, viral infections, autoimmune diseases, neurodegenerative disorders, and AIDS (acquired immunodeficiency syndrome), may be influenced by changes in cell survival, according to studies. Some of these diseases may not progress naturally unless specific therapies that change the apoptotic threshold are used.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V55019 | Relfovetmab | 2171034-70-9 | Relfovetmab is an anti-NGF monoclonal antibody (mAb). |
|
V55004 | Remtolumab (ABT-122) | 1791410-27-9 | Remtolumab (ABT-122) is a bivariable domain immunoglobulin that neutralizes tumor necrosis factor alpha (TNFα) and IL-17A. |
|
V38955 | Reveromycin A | 134615-37-5 | Reveromycin A is a benzoquinone antibiotic extracted from the genus Streptomyces and is a selective inhibitor of protein synthesis in eukaryotic cells. |
|
V34614 | Rhapontin | 155-58-8 | Rhapontin (Rhaponiticin) is a component of Rheum officinale Baill. |
|
V38425 | RI-962 | 2763831-53-2 | RI-962 is a potent and specific receptor-interacting protein kinase 1 (RIPK1) inhibitor. |
|
V38377 | Rigosertib sodium (regosertib sodium; ON-01910 sodium) | 592542-60-4 | Rigosertib sodium (ON-01910 sodium) is a multikinase inhibitor and selective anticancer agent that causes apoptosis by inhibiting the PI3K/Akt pathway, promotes the phosphorylation of histone H2AX and induces the G2/M phase of the cell cycle. |
|
V56389 | Rilmenidine-d4 | 85047-14-9 | Rilmenidine-d4 is the deuterated form of Rilmenidine. |
|
V54989 | RIP1kinase inhibitor 4 | 2919836-00-1 | RIP1 kinase inhibitor 4 (Example 3) is a RIP1 kinase inhibitor that can penetrate the BBB (blood-brain barrier) (EC50= <100 nM). |
|
V54990 | RIP1kinase inhibitor 5 | 2428422-17-5 | RIP1 kinase inhibitor 5 (example 1) is a potent RIP1 inhibitor used as a checkpoint kinase to control tumor immunity. |
|
V54988 | RIP1kinase inhibitor 6 | 2428401-62-9 | RIP1 kinase inhibitor 6 is a potent and specific RIP1 kinase inhibitor (antagonist) with |
|
V54985 | RIP1kinase inhibitor 7 | 2428401-23-2 | RIP1 kinase inhibitor 7 (compound 41) is a potent receptor-interacting protein 1 kinase (RIP1) inhibitor (antagonist) with IC50 of <100 nM for human RIP1. |
|
V54983 | RIP1kinase inhibitor 8 | 2226735-54-0 | RIP1 kinase inhibitor 8 (Compound 77) is a potent and selective dihydropyrazole (DHP) RIP1 kinase inhibitor (antagonist) with IC50 of 20 nM. |
|
V85303 | RIPK1-IN-18 | 2682889-01-4 | |
|
V85350 | RIPK1-IN-18 sulfate hydrate | 2897618-64-1 | |
|
V85164 | RIPK1-IN-19 | 2763831-43-0 | |
|
V85065 | RIPK1-IN-20 | ||
|
V54987 | RIPK2-IN-3 | 1290490-78-6 | RIPK2-IN-3 (FCG806791773) is a RIPK2 inhibitor. |
|
V85848 | RIPK2-IN-4 | ||
|
V85867 | RIPK2-IN-5 | 2885227-09-6 | |
|
V38352 | RIPK3-IN-1 | 2361139-70-8 | RIPK3-IN-1 is a type II RIPK3 DFG-out site inhibitor (antagonist) with IC50 of 9.1 nM. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
